JOHN S. POWERS JR.
Since the introduction of Dicumarol in 1941 its usefulness as an anticoagulant has been critically studied by many clinicians and investigators.1-15 Initially its use was restricted to the treatment of periperal thromboembolic disease. However, the American Heart Association has carried out an extensive investigation of its efficacy in the prevention of complications of myocardial infarction.
Wright and Foley1 reviewed the use of anticoagulants in heart disease and gave preliminary observations concerning the large study now in progress. They stated, "Results appear to demonstrate conclusively that this form of therapy is the most satisfactory used to date." Parker and Barker2
POWERS JS. TOXICITY OF DICUMAROL: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES1. Ann Intern Med. ;32:146–152. doi: 10.7326/0003-4819-32-1-146
Download citation file:
Published: Ann Intern Med. 1950;32(1):146-152.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use